Company intelligence / Profile preview
Kymera Therapeutics
Watertown, Massachusetts, United Stateskymeratx.com ↗
- Ownership
- Public · KYMR
- Development stage
- Phase 1
01
Overview
Kymera has advanced multiple first-in-class oral targeted protein degraders into clinical development. KT‑474/ SAR444656 targets IRAK4 for immune-inflammatory diseases and has entered Phase 2 trials with Sanofi as a partner. KT‑621 targets STAT6 for allergic/inflammatory diseases and has shown promising preclinical results. The company’s oncology pipeline includes KT‑253 targeting MDM2 in AML with orphan drug designation from the FDA. Additional programs target hematological malignancies via IRAKIMiD compounds.[3][4]
- Therapeutic areas
- OncologyImmunologyDermatology
- Modalities
- Targeted protein degraders (small molecules)[1][2][4]
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Sanofi – partnered on development of KT‑474/SAR444656 for immune-inflammatory diseases with profit-sharing in the US and royalties ex-US[3]NEOsphere Biotechnologies – partnership to identify new molecular glue targets[4]
04
Financials
- Market cap
- $10.9B
- Total revenue
- $39.2M
- Enterprise value
- $10B
Beyond the preview
Go deeper on Kymera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kymera Therapeutics.